More investor suits were brought against life sciences companies in 2019 than in any of the past five years, according to a new report from law firm Dechert LLP. The increase continues a trend that has seen the number of such suits more than double since 2014.

Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.

A look back at Medtech Insight’s five most-read Market Intelligence features of 2019 reveals a diverse mix of interests among our readers – hemodialysis, robotic surgeries, ophthalmic surgical solutions, liquid biopsy and digital technologies that seek to improve women's health.

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?